Exhibit 10.4
------------
MYRIAD GENETICS, INC. HAS OMITTED FROM THIS EXHIBIT 10.4 PORTIONS OF THE
AGREEMENT FOR WHICH MYRIAD GENETICS, INC. HAS REQUESTED CONFIDENTIAL TREATMENT
FROM THE SECURITIES AND EXCHANGE COMMISSION. THE PORTIONS OF THE AGREEMENT FOR
WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED ARE MARKED "[ ]" AND SUCH
CONFIDENTIAL PORTIONS HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
March 4, 1996
Dr. Lisa Cannon-Albright
Genetic Epidemiology
University of Utah
391 Chipeta Way #D-2
Salt Lake City, Utah 84108
RE: Sub-contract titled: Isolation and Characterization of Genes
Predisposing to Cancer. University Acct. No. 5-20639
Dear Dr. Cannon-Albright:
This modification is made and entered into by and between the University of Utah
and Myriad Genetics, Inc. As the original agreement states, any extension must
be mutually agreed upon in writing between the parties.
The purpose of this modification is to approve an additional [
]
The Principal Investigator will be Lisa Cannon-Albright for this new year
funding.
Approval Signatures: Myriad Genetics, Inc.
/s/ Peter Meldrum
-------------------------------
Peter Meldrum-President
Genetic Epidemiology
/s/ Dr. Lisa Cannon-Albright
-------------------------------
Dr. Lisa Cannon-Albright
University of Utah
/s/ Robert G. Glass
-------------------------------
Acting for
Nancy V. Dyke, Associate Director
Office of Sponsored Projects
-2-
BUDGET FOR [
]
-3-